الذبحة الصدرية الدقيقة
Cardiac syndrome X
مراجعة من قبل الدكتورة توني هازيل، زميلة الكلية الملكية للأطباء العامينآخر تحديث بواسطة الدكتور كولين تايدي، MRCGPآخر تحديث 22 سبتمبر 2023
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- Ask Patient
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
المهنيين الطبيين
تم تصميم مقالات المراجع المهنية لاستخدامها من قبل المتخصصين في الرعاية الصحية. يتم كتابتها بواسطة أطباء من المملكة المتحدة وتستند إلى أدلة بحثية وإرشادات المملكة المتحدة وأوروبا. قد تجد الذبحة الصدرية الدقيقة مقالة أكثر فائدة، أو واحدة من مقالاتنا الأخرى مقالاتنا الصحية.
Synonyms: microvascular angina
ما هي الذبحة الصدرية الدقيقة؟
Microvascular Angina (previously known as Cardiac syndrome X (CSX)) is characterised by angina-like chest discomfort, ST-segment depression during exercise, and normal coronary arteries at angiography. CSX is much more common in women than in men. CSX is not necessarily benign and is linked to adverse cardiovascular outcomes and a poor quality of life.1 2 3
There is no standard agreed definition for CSX.4 There are numerous causes for chest pain in patients with CSX that range from non-cardiac to coronary microvascular dysfunction (CMD).5 However, the term CSX is often used synonymously with CMD.
Myocardial ischaemia may result from different types of functional disease involving the coronary arteries (eg, coronary artery vasospasm), the coronary microcirculation or both. An accurate assessment of these components after exclusion of organic coronary artery disease (CAD) is very important because a correct diagnosis has relevant prognostic and therapeutic implications.2
There is a separate Coronary Artery Vasospasm article. The remainder of this article is mainly focused on CMD. The cause of microvascular angina seems very likely to be organic and functional abnormalities of the small arteries of the heart.6
Diabetes mellitus, coronary artery spasm, left ventricular hypertrophy and cardiomyopathy preclude the diagnosis of CMD.7
How common is microvascular angina? (Epidemiology)8
The prevalence of microvascular angina appears to have increased over the past few years because of increased diagnostic imaging, with a recent study reporting that of 400,000 individuals undergoing diagnostic angiography for suspected coronary artery disease, over 50% were found to have either no coronary artery disease or non-obstructive coronary artery disease.
Recent studies also showed that coronary microvascular dysfunction is identified in 4 in 5 patients with suspected microvascular angina or vasospastic angina.
Coronary microvascular dysfunction can occur in both men and women but recent reports and studies indicate that it is more prevalent in women (especially post-menopause).
عوامل الخطر
These are in common with CAD and include:9
مقاومة الإنسولين or overt داء السكري.
Low-grade chronic inflammation.
Microvascular angina symptoms (presentation)8
Patients with microvascular angina can present with exertional retrosternal chest pain/pressure or discomfort or have exertional dyspnoea. Symptoms may also develop during exercise, after exercise or even at rest and are relatively less likely to be relieved by nitrates compared with obstructive coronary artery disease.
Duration of symptoms are variable, tend to be prolonged and may differ in nature, ie stabbing pain, jaw pain or back pain.
Although symptoms can be the initial presentation in microvascular angina, there is a high prevalence of silent ischaemia in women with coronary microvascular dysfunction.
علامات
There are no characteristic clinical signs but examination may reveal underlying cardiovascular risk factors - eg, hypertension and obesity.
انظر أيضًا إلى المقالة حول الذبحة الصدرية المستقرة.
التشخيص التفريقي10
The whole spectrum of causes of chest pain must be considered. See the separate ألم الصدر و ألم الصدر من النوع القلبي في الرعاية الأولية articles. However, possible differential diagnoses for special consideration are:
التحقيقات8
Investigations should be as for CHD:
FBC (to exclude anaemia or polycythaemia).
U&E (if starting an angiotensin-converting enzyme (ACE) inhibitor).
LFTs (before starting a statin).
Fasting lipids (with a view to adjustment by diet or drugs).
Fasting blood glucose (may show impaired glucose tolerance or overt diabetes).
Non-cardiac aetiologies of chest pain, including musculoskeletal, psychiatric, gastrointestinal and pulmonary disorders, must be excluded. Those with angina-like chest pain and even some with atypical features, including more frequent or persistent pain and inconsistent response to sublingual nitrates, should undergo stress testing.
Investigations for microvascular angina include non-invasive methods such as:
Transthoracic Doppler, contrast echocardiography.
Cardiac positron emission tomography (PET).
Cardiac MRI.
Cardiac CT.
Invasive testing11
Coronary microvascular function in patients with angina and non-obstructive coronary artery disease should be evaluated invasively. The two tools that could be used are an intracoronary Doppler wire or an intracoronary thermodilution-derived method that measure the response of coronary blood flow under vasoactive stimuli. The most used is the thermodilution method.
Adenosine is the drug usually used for this aim at the dose of 140 μg/Kg/min that could be administered intravenously or intracoronary. However, the diagnostic accuracy is improved by the use of intracoronary acetylcholine that induces in normal patients a microvascular dilation.
Technical innovations have enabled the measurement of absolute coronary flow and minimal microvascular resistance by continuous thermodilution through the use of a dedicated microcatheter and dual-sensor intracoronary guidewires.
Microvascular angina treatment and management8
Treatment of CSX includes lifestyle modification and anti-anginal, anti-atherosclerotic and anti-ischaemic medications.
Non-pharmacological options include cognitive behavioural therapy, enhanced external counterpulsation, neurostimulation and stellate ganglionectomy.1
Effective treatment of microvascular angina requires aggressive risk factor modification (exercise is one of the most effective treatment modalities). Several other treatment strategies have been shown to relieve anginal symptoms as well as improve vascular function, including beta-blockers, ACE inhibitors, ranolazine, L-arginine and statins. Oestrogen replacement therapy may also have a role for affected women. Nitrates may be effective for symptom relief.12
Other treatments include relaxation techniques, hypnotherapy and العلاج السلوكي المعرفي.
إجراءات عامة
Exercise regimes have a beneficial effect.13
Weight loss reduces insulin resistance.
Stop smoking if applicable.
دوائي11
The current medical therapy for angina in patients with obstructive coronary artery disease, like beta-blockers and calcium channel blockers, is the standard treatment for microvascular angina.
Medications for the control of blood pressure, like ACE inhibitors, are demonstrated to improve coronary flow reserve in coronary microvascular disfunction and can be easily combined with other antianginal drugs like beta-blockers and calcium antagonists.
Beta-blockers with vasodilatory properties like nebivolol and carvedilol have been shown to be the most effective.
Calcium channel blockers like amlodipine, verapamil and diltiazem, induce vascular smooth muscle cell relaxation by blocking the influx of calcium and reduce the myocardial oxygen consumption.
Ranolazine may improve exercise capacity and symptoms, decreasing calcium and sodium overload in cardiac cells, due to the inhibition of late inward sodium.
علاجات أخرى5
Spinal cord stimulators and enhanced external counterpulsation (EECP) have been studied in patients with chest pain without obstructive CAD. Spinal stimulation is believed to modulate pain-related nerve signals and increase myocardial blood flow though effects on sympathetic tone. EECP increases diastolic blood flow to the heart.
التكهن14
Patients with coronary microvascular disfunction have been reported to have a poor prognosis due to several factors like impaired quality of life and higher risk of major cardiovascular adverse events, especially in the postmenopausal women.
Patients with microvascular angina have a 1.5-fold increase in mortality compared with those without any evidence of myocardial ischaemia. In addition, more than 40% of patients are re-admitted to the hospital for chest pain and 30% undergo repeat coronary angiography. They also have a worse quality of life when compared to healthy counterparts.
Therefore, many patients with chest pain, without significant obstruction on coronary angiography, are often inappropriately reassured and remain untreated.
الوقاية
The risk factors for coronary microvascular disfunction are similar to those for obstructive coronary artery disease. Therefore see also the article on الوقاية من أمراض القلب والأوعية الدموية.
تحديثات حصرية لمتخصصي الرعاية الصحية
ابقَ على اطلاع بأحدث التحديثات السريرية، والرؤى المهنية، والإرشادات المستندة إلى الأدلة. تقوم نشرة Patient Pro الإخبارية بتجميع محتوى أساسي لمتخصصي الرعاية الصحية - يتم تسليمه مباشرة إلى بريدك الوارد.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.
قراءة إضافية ومراجع
- Del Buono MG, Montone RA, Camilli M, et al; Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 Sep 28;78(13):1352-1371. doi: 10.1016/j.jacc.2021.07.042.
- Vancheri F, Longo G, Vancheri S, et al; Coronary Microvascular Dysfunction. J Clin Med. 2020 Sep 6;9(9):2880. doi: 10.3390/jcm9092880.
- Bairey Merz CN, Pepine CJ, Shimokawa H, et al; Treatment of coronary microvascular dysfunction. Cardiovasc Res. 2020 Mar 1;116(4):856-870. doi: 10.1093/cvr/cvaa006.
- Bradley C, Berry C; Definition and epidemiology of coronary microvascular disease. J Nucl Cardiol. 2022 Aug;29(4):1763-1775. doi: 10.1007/s12350-022-02974-x. Epub 2022 May 9.
- Agrawal S, Mehta PK, Bairey Merz CN; Cardiac Syndrome X: Update. Heart Fail Clin. 2016 Jan;12(1):141-56. doi: 10.1016/j.hfc.2015.08.012.
- Radico F, Cicchitti V, Zimarino M, et al; Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease: practical considerations for diagnostic tests. JACC Cardiovasc Interv. 2014 May;7(5):453-63. doi: 10.1016/j.jcin.2014.01.157. Epub 2014 Apr 16.
- Montalescot G, Sechtem U, Achenbach S, et al; إرشادات ESC لعام 2013 حول إدارة مرض الشريان التاجي المستقر: فريق العمل لإدارة مرض الشريان التاجي المستقر في الجمعية الأوروبية لأمراض القلب. Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30.
- Vermeltfoort IA, Raijmakers PG, Riphagen II, et al; Definitions and incidence of cardiac syndrome X: review and analysis of clinical data. Clin Res Cardiol. 2010 Aug;99(8):475-81. Epub 2010 Apr 21.
- Marinescu MA, Loffler AI, Ouellette M, et al; Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC Cardiovasc Imaging. 2015 Feb;8(2):210-20. doi: 10.1016/j.jcmg.2014.12.008.
- Suzuki H; Different definition of microvascular angina. Eur J Clin Invest. 2015 Dec;45(12):1360-6. doi: 10.1111/eci.12552. Epub 2015 Nov 18.
- Kuruvilla S, Kramer CM; Coronary microvascular dysfunction in women: an overview of diagnostic strategies. Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1515-25. doi: 10.1586/14779072.2013.833854.
- Aldiwani H, Mahdai S, Alhatemi G, et al; Microvascular Angina: Diagnosis and Management. Eur Cardiol. 2021 Dec 2;16:e46. doi: 10.15420/ecr.2021.15. eCollection 2021 Feb.
- Crea F, Camici PG, Bairey Merz CN; Coronary microvascular dysfunction: an update. Eur Heart J. 2014 May;35(17):1101-11. doi: 10.1093/eurheartj/eht513. Epub 2013 Dec 23.
- Agrawal S, Mehta PK, Bairey Merz CN; Cardiac Syndrome X: update 2014. Cardiol Clin. 2014 Aug;32(3):463-78. doi: 10.1016/j.ccl.2014.04.006. Epub 2014 Jun 2.
- Spione F, Arevalos V, Gabani R, et al; Coronary Microvascular Angina: A State-of-the-Art Review. Front Cardiovasc Med. 2022 Mar 30;9:800918. doi: 10.3389/fcvm.2022.800918. eCollection 2022.
- Duvernoy CS; Evolving strategies for the treatment of microvascular angina in women. Expert Rev Cardiovasc Ther. 2012 Nov;10(11):1413-9. doi: 10.1586/erc.12.55.
- Banks K, Lo M, Khera A; Angina in Women without Obstructive Coronary Artery Disease. Curr Cardiol Rev. 2010 Feb;6(1):71-81.
- Park JJ, Park SJ, Choi DJ; Microvascular angina: angina that predominantly affects women. Korean J Intern Med. 2015 Mar;30(2):140-7. doi: 10.3904/kjim.2015.30.2.140. Epub 2015 Feb 27.
حول المراجععرض السيرة الذاتية الكاملة

Dr Toni Hazell, FRCGP
بكالوريوس الطب والجراحة، بكالوريوس العلوم، زميل الكلية الملكية للأطباء العامين، دبلوم في الصحة الجنسية والإنجابية، دبلوم في طب الجهاز البولي التناسلي، دبلوم الكلية الملكية لأطباء النساء والتوليد، دبلوم في صحة الطفل (لندن، المملكة المتحدة، 2000)
تخرجت الدكتورة توني هازيل من كلية الطب بمستشفى سانت ماري وأكملت تدريبها في مستشفى نورثويك بارك.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
المراجعة التالية مستحقة: 20 سبتمبر 2028
22 سبتمبر 2023 | أحدث إصدار
المزيد في أمراض القلب والأوعية الدموية
- الفحوصات القلبية
- تقييم مخاطر القلب والأوعية الدموية
- الأحداث الدماغية الوعائية
- تحديد اضطرابات النظم بواسطة تخطيط القلب
- متلازمة آيزنمنغر
- رباعية فالو
- السفر بالطائرة مع الحالات الطبية
- التهاب الشرايين ذو الخلايا العملاقة
- ارتفاع ضغط الدم
- تخثر الوريد داخل الجمجمة
- انسداد الأطراف ونقص التروية
- تدلي الصمام التاجي
- الرعاية التلطيفية لفشل القلب
- مرض رينود
- النوبات الانعكاسية اللاهوائية
- تمزق تمدد الشريان الأورطي
- تسرع القلب فوق البطيني لدى البالغين
- تورم الساقين
- التهاب الشرايين تاكاياسو
- النوبات الإقفارية العابرة


